We Need New Antimicrobials To Prevent the Next Infectious Disease Crisis


By John Rex and Kevin Outterson

Imagine if scientists had seen Covid-19 coming years in advance yet did little to prepare. Unthinkable, right?

Yet that's exactly what's happening with another infectious disease crisis -- the one caused by antibiotic-resistant bacteria and fungi. So-called superbugs already kill more than 700,000 people each year. And the World Health Organization warns that by 2050 the annual death toll could reach 10 million if we don't use the time to get prepared.

The antibiotics and other antimicrobial drugs needed to prevent such a calamity don't yet exist -- and they're years away from patients. The problem isn't a lack of willing scientists, but rather a broken marketplace that has made it virtually impossible for researchers to attract adequate funding.

Unless lawmakers take steps to jump-start antimicrobial innovation, the world will soon find itself unprepared for a global health emergency as deadly as Covid-19.

Bacteria and fungi resistant to drugs have been around as long as the drugs themselves. When a patient takes an antimicrobial, microbes generally die. But some can survive, with the potential to become immune to existing antimicrobials.

Innovation in antimicrobials has slowed dramatically in recent years, with higher rates of failure. In the last two decades, researchers have developed just two completely new kinds of antibiotics.

The window for avoiding a superbug crisis that kills millions of people each year is closing quickly. Pulling back from the brink will require a two-pronged approach.

First, we must encourage doctors to prescribe antibiotics as smartly and sparingly as possible. We must also educate patients about what antibiotics can actually do, what they can't do, and their limitations.

Second, we need a large-scale effort to create newer, more effective antimicrobials. That will require addressing the fundamentally broken market for these drugs.

Medicines are incredibly expensive to develop, with median R&D costs for a single antibiotic reaching $1 billion.

Pharmaceutical companies can justify such investments only if they have a fighting chance to recoup their costs. But here's the rub: A new, advanced antibiotic is reserved for emergencies, meaning a company would sell relatively few doses of it and almost certainly lose money.

That's why pharmaceutical firms have moved away from antibiotic research in recent years. Four decades ago, there were 18 major drug companies pursuing new antibiotics. Today, there are only three.

Two reforms currently before Congress could help break this research logjam.

The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act would allow Medicare to pay hospitals more for using advanced antibiotics when appropriate. This would raise the demand for more sophisticated medicines, thus giving drug makers the confidence to invest in antibiotics research.

Another bill, the proposed Pioneering Antimicrobial Subscriptions to End Up Surging Resistance (PASTEUR) Act, takes a different tack. It would allow the government to pay a subscription for unlimited access to a new antimicrobial. This, in turn, would enable drug companies to recover their costs, while ensuring that public health authorities have plenty of doses available, if needed.

America's pharmaceutical industry is also prepared to bridge the gap. More than 20 of our country's leading drug companies recently helped launch the AMR Action Fund, a partnership to invest more than $1 billion in antibiotic research and development with the goal of supporting later stages clinical trials so that two to four new antibiotics would reach approval by 2030.

But these companies can't go it alone, and the antibiotics they develop won't be available to patients unless the companies can stay in business. Lawmakers must act to improve the pipeline of new antimicrobial drugs -- and quickly.

If they don't, the world could soon face an infectious disease crisis as formidable as Covid-19.

Kevin Outterson is the founder and executive director of CARB-X and a professor at Boston University School of Law. CARB-X is a global nonprofit partnership that focuses on supporting the developers of promising new antibiotics, diagnostics, and vaccines; it is funded by BARDA, the Wellcome Trust, and the National Institute of Allergy and Infectious Diseases. John Rex is the chief medical officer at F2G Limited, a company focused on treatments for rare fungal diseases, and the founder of AMR Solutions. Both Outterson and Rex are members of the scientific advisory board of the Partnership to Fight Infectious Disease. The opinions expressed are their own and not necessarily those of their companies or organizations.

More Resources


03/27/2024
Biden, Trump Know RFK Jr.'s VP Choice a Game Changer


more info


03/27/2024
Republican 'War on Women' Is a Media Myth
There's no evidence Republicans want to ban birth control. On the contrary, the GOP has led on efforts to make it easier to get birth control over the counter.

more info


03/27/2024
Supreme Court Scoffs at Flimsy Abortion Pill Argument


more info


03/27/2024
NBC's Failed Attempt To Appeal to MAGA Voters
I spent years in the MAGA cult: We loathed Ronna Romney McDaniel almost as much as we loathed the media

more info


03/27/2024
Democrats Are Better for the US Economy
Jeffrey Frankel notes that this is no mere correlation, though the cause remains an enduring puzzle.

more info


03/27/2024
TikTok's Dangerous Influence Over Kids
Congressional talk about TikTok needs to be a wake-up call to parents. The Chinese app exposes kids to dangerous content, especially about suicide. It's 'every parents's nightmare.'

more info


03/27/2024
Smartphones Rewired Childhood. Here's How to Fix It.
Phones have made kids sedentary, solitary, anxious, and depressed. But, says the author and psychologist, we can reverse the damage.

more info


03/27/2024
NBC Cements Status as Anti-Trump, Pro-Biden Network
The dramatic saga following NBC's announced hire of former RNC chair Ronna McDaniel solidified the network's position as being fully anti-Trump going into the 2024 election.

more info


03/27/2024
Don't Tell This 'Double-Hater' She's Crazy
Most of those known as 'double haters' will come around to support one of the two major party presidential nominees. But some, like Victoria Thompson, won't back Trump or Biden under any circumstances.

more info


03/27/2024
Joe Biden, the (Still) Unpopular President
There's been a lot of wishful reporting about the political fortunes and reelection hopes of President Joe Biden.

more info


03/27/2024
Trump's Crumbling Empire Gives Biden a Golden Opportunity
Here's a phrase I never thought I'd say: Donald Trump, Bible salesman.

more info


03/27/2024
Democrats Distort the Law To Subvert 2024 Election
An appeals court just gutted New York's $454 million fine against Trump in ‘a fraud case in which there are no fraud victims.'

more info


03/27/2024
RFK Jr. Makes New Play for Disaffected w/Nicole Shanahan
Mr. Kennedy's allies hope his choice of a wealthy Silicon Valley lawyer to be his running mate will inject new energy and financial support into his independent bid for the White House.

more info


03/27/2024
SCOTUS Must Rely on 1st Amendment Censorship Case
The justices of the Supreme Court never focused on the First Amendment's words when hearing arguments in Murthy v. Missouri last week. The case challenges the federal government's orchestration of social media censorship, so one might have expected the justices to pay some attention to the First Amendment itself.

more info


03/27/2024
The Republican House Fails the Ronald Reagan Test
Following its Friday failure to deliver a new package of aid for Ukraine, it's time for a title change in the US House of Representatives.

more info



Custom Search

More Politics Articles:

Related Articles

Congress: Let's Talk About Trade Enforcement


The Trump administration has set an ambitious trade agenda for the remainder of 2020. In a House Ways and Means Committee hearing earlier this summer, U.S. Trade Representative Robert Lighthizer stressed the president's intent to crack down on foreign countries that discriminate against American business and innovators.

With Biomedical Research, Taxpayers are Getting a Great Deal


Gilead Sciences' novel drug remdesivir has shown immense promise for treating coronavirus. Yet every time a company develops a promising drug, some policymakers call for the government to take control of the compound in question.

Marx on Christianity, Judaism, and Evolution/Race


"If someone calls it socialism," said the Rev. William Barber at an August 2019 conference of the Democratic National Committee, "then we must compel them to acknowledge that the Bible must then promote socialism, because Jesus offered free health care to everyone, and he never charged a leper a co-pay."

Abusing March-in Rights Would Jeopardize COVID-19 Research


Thirty-one state attorneys general recently urged the Trump administration to disregard the intellectual property protections on remdesivir -- the only FDA-approved treatment for COVID-19 -- and then license its patents to multiple drug manufacturers.

Judge Amy Coney Barrett and the Purdue Sexual Assault Case


Will some senators on the Senate Judiciary Committee vilify Judge Amy Coney Barrett, President Trump's Supreme Court nominee? Attacks on her religion, her large family, or claims that she will block the advance of women may make good fodder for Facebook, but senators who pursue those tacks are likely to reap public disapproval from their own constituents. What is more likely is that liberal senators will take a page from liberal/progressive organizations like Public Justice and portray Barrett as soft on and complicit with campus sexual abusers. How?

President Trump's Executive Order Will Put an End to Pharmaceutical Breakthroughs


Every day, scientists get closer to a COVID-19 vaccine. A handful of biopharmaceutical firms hope to make one available by year's end.

The Mayflower Mystique: Remembering the Pilgrims


Few can name which groups the Godspeed and the Arabella brought to America. They were the Jamestown colonists in 1607 and the Puritans to Massachusetts Bay Colony in 1630, respectively. But the Mayflower, which brought the Pilgrims to Plymouth in 1620, has sailed into history and ranks with the Titanic, the Lusitania, the Bismarck, and the Queen Mary as the world’s most famous ships. What accounts for the Mayflower’s mystique?

COVID's Second Wave Underscores the Threats Facing Disabled Americans


The second wave of COVID-19 has arrived with a vengeance.

Triumph of the Vaccine—No Shape-Shifting Enemy


Here’s a thought experiment. What if our experience with COVID-19 turns out to be a warm-up for responding to a worse plague in the future? COVID-19 is devastating for a significant number of older people but relatively innocuous for the young. I am thankful that this is not like the Justinian plague, nor the Athenian one, nor like smallpox. What if—God forbid—we find ourselves hosting a plague like one of these? Something as deadly as Ebola but as infectious as SARS-CoV-2?

Who is Perfect? Biden, Trump, McConnell, Pelosi?


Democrats have proven once again that they can find fault in President Donald Trump. Faults and flaws were found in him before the election. Many years before politics there were never any rave reviews about him being perfect.

The 340B Prescription-Drug Swindle Has Gone on Long Enough


In a recent hearing, California Attorney General Xavier Becerra revealed just how unfit he is to lead the Department of Health and Human Services.

Vaccination is the Ticket to Getting the U.S. Back On Track


The end of the pandemic in the U.S. is in sight. The Covid-19 vaccines currently available in the United States have proven to be outstandingly effective at protecting recipients from coronavirus and they are also safe.

Private Deborah Sampson, 'The Female Soldier'


There are those who would say that Private Deborah Sampson deserved the Medal of Honor, but she didn’t sign up for that; she joined the Army to fight for her country and wound up making history. Private Sampson was America’s first woman combat soldier. She served, disguised as a man by the name of Robert Shurtleff, under the command of General George Washington in the Continental Army during the American Revolution.

The End of Covid-19 Could Start in the Hair Salon


President Biden has floated an ambitious goal -- vaccinate enough Americans to achieve some sense of normalcy by July 4.

President Biden Is Right to Redefine Infrastructure


President Biden is in ongoing talks to discuss his multi-trillion-dollar infrastructure plan. Ever since its release, critics have claimed that many aspects of the plan have nothing to do with infrastructure.

America Needs Strong Patent Laws to Keep Inventing


In May, the Biden administration announced its support for a proposal at the World Trade Organization to suspend international intellectual property protections on Covid-19 vaccines.